Category Archives: Eczema

JUPITER, FL / ACCESSWIRE / November 11, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing cannabinoid receptor agonists for the treatment of eczema, actinic keratosis, burns, and herpes cold sores, announced that it has received an official written response from a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for JW-100, a topical drug the treatment of eczema.

The main purpose of the pre-IND meeting was to evaluate the drug development plan for JW-100.

Jupiter Wellness believes that the written response from the FDA supports the Company's approach and its overall drug development strategy to enable the filing of an IND for its clinical studies on JW-100.

Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness, stated, "The pre-IND meeting written response marks an important milestone in the development of JW-100 for the treatment of eczema. We have obtained FDA concurrence and clear guidance on the proposed manufacturing, nonclinical pharmacology, and toxicology studies, and the Phase 1 clinical design."

JW-100 met its primary endpoint in a recently completed Phase 1-equivalent international study in which Jupiter's topical formulation cleared or reduced eczema following two weeks of use. These results suggest JW-100 may potentially prove superior to existing prescription drugs for the treatment of eczema in future clinical trials. The global eczema treatment market is valued at $10 billion and expected to grow at a CAGR of 13% from 2020-2025.

About Jupiter WellnessJupiter Wellness, Inc. (NASDAQ:JUPW) is a leading developer of skincare therapeutics and treatments. The Company's product pipeline of enhanced skincare therapeutics focuses on the endocannabinoid system to address indications including psoriasis, eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenue from a growing line of proprietary over-the-counter skincare products including its CaniSun sunscreen and other wellness brands sold through http://www.cbdcaring.com.

Story continues

For additional information, please visit http://www.jupiterwellness.com. The Company's public filings can be found at http://www.Sec.gov.

Safe Harbor StatementTo the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company's industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor & Public Relations Contact InfoPhone: 561-462-2700Email: info@JupiterWellness.com

SOURCE: Jupiter Wellness, Inc.

View source version on accesswire.com: https://www.accesswire.com/672218/Jupiter-Wellness-Completes-Pre-IND-meeting-with-the-US-Food-Drug-Administration-for-JW-100-in-the-Treatment-of-Eczema

Read the original post:
Jupiter Wellness Completes Pre-IND meeting with the U.S. Food & Drug Administration for JW-100 in the Treatment of Eczema - Yahoo Finance

Id describe the finish as more satin than dewy, but its definitely not flat the way most matte foundations can be. When I spoke to Kirin Bhatty, a celebrity makeup artist who helped develop the formula, she said this was intentional. She wanted to give people the option to add shine wherever they wanted (cheekbones, temples), as opposed to blanketing their entire faces in it (which doesnt tend to photograph well or work for everyones skin).

Ive been using Sunny Days almost daily for over a month now, and I am happy to report that it has not once aggravated my eczema. I get the UV protection I need, plus a subtle veil of color that evens out my complexion. And I really enjoy using it.

In a sea of plain white tubs and creams, this cheery lavender tube gives me a taste of the fun I used to have with beauty products before eczema. Its easy to apply, it looks good on my skin and is the rare product that does exactly what it says, which is why I plan on using it even when Im not in the middle of another flareup.

Try it ($30)

RELATED: The Best Makeup for Sensitive Skin, According to a Beauty Editor with Eczema

See the rest here:
Hi, Have Eczema? You Might Want to Try Tower28 Sunny Days Tinted Sunscreen Foundation - PureWow

Chhath Puja 2021 Special | Do not bathe in the toxic foam-filled Yamuna River, it may lead to severe skin infections, like Atopic Dermatitis, Cancer, etc.

Written by Satata Karmakar | Updated : November 10, 2021 10:56 AM IST

Avoid bathing in the Yamuna river on the Chhath Puja, it may damage your skin cells, lead to skin irritation and atopic dermatitis due to the toxic foam present in it right now, health experts warned the devotees intending to take a dive to celebrate the festival. How does the toxic foam affect your skin? According to the experts, bathing in the river's toxic foam can cause drying of the skin and severe eczema.

Ammonia and phosphate levels in the Yamuna river caused by the industrial pollutants have been rising at an alarming rate leading to the formation of hazardous foam at many places. Talking to the media, leading dermatologist, Dr. Deepali Bhardwaj said that exposure to this hazardous foam can lead to skin allergies, irritation, and many types of skin pigmentation. She further added those with a family history of autoimmune diseases like diabetes and thyroid can definitely experience this earlier and in varied forms. Also, vitiligo or other autoimmune diseases can get triggered by industrial pollution in the water. "Skin cancer has also occurred besides common bacterial and viral infections like tuberculosis, viral warts, etc. which can spread from one person to another," she said.

Explaining more about the effects of the toxic foam on the skin, another leading expert in the field of Cancer, Dr. Anshuman Kumar said: "If this water, which has a high concentration of ammonia, is swallowed, these chemicals can cause serious damage to the lungs and lead to gastrointestinal problems and diseases like typhoid." She went on to add, "Long-term exposure to heavy metals like lead, mercury, and arsenic may cause hair fall, conjunctivitis, and hormonal imbalances."

Chhath Puja is an ancient Hindu Vedic festival historically which is celebrated in India especially in the states like Bihar, eastern Uttar Pradesh and, Jharkhand. On this particular day, the devotees take a dive in the river to mark the occasion. However, following the increasing amount of toxic foam in the river, the experts have warned that the devotees must take precautions before taking bath in the Yamuna. "Devotees should apply coconut oil before going into the river as it forms a barrier for some time and can prevent skin irritation," Dr. Sardana said. He further advised, "Avoid wearing synthetic clothes as they leach out allergens. Cotton clothes are ideal. Preferably an old dress will do as that leads to less chance of chemical-induced allergy."

(With inputs from Agencies)

Follow us on

View original post here:
Chhath Puja 2021: Bathing In Yamuna's Toxic Foam Can Damage Your Skin, Lead To Severe Eczema, Warn Experts - TheHealthSite

Carina Venter, PhD, RD, allergy specialist dietitian and associate professor in pediatric allergy and immunology at Children's Hospital Colorado and the University of Colorado, discusses the gut microbiomes complex relationship with our immune system and diet diversitys potential role in allergic disease and food allergyrelated outcomes.

She presented Can the Microbiome be Manipulated to Prevent Food Allergy during the symposium, Solving the Puzzle of Food Allergy Prevention, at this years American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Transcript

How does the gut microbiome contribute to the immune systems reaction to certain allergens?

I think it's a very complex situation, which I'm trying to explain in a few simple sentences. In short, we know that the gut microbiome, particularly a more diverse gut microbiome, produces certain short-chain fatty acids; that's really been the aspects that I've been looking at. Clearly, there's many other metabolites that are produced by the gut microbiome. But in terms of the short-chain fatty acids, it seems that for now, butyrate is the most important fatty acid. Butyrate sort of has crosstalk with the immune system. It upregulates, or increases, the function of the T regulatory cells. The T regulatory cells just try and calm everything down againif I can put it in simple terms. Really, in short, if we have a healthier or more diverse gut microbiome, which can help us to make more butyrate, perhaps we'll find that our immune system will be more tolerant to all the food allergens that we put into our gut.

How does the microbiome affect different types of atopic diseases?

That's a really good question: whether diet diversity affects all allergic disease outcomes in the same way. Im first author of an [European Academy of Allergy and Clinical Immunology] EAACI position statement, where we looked at diversity in infancy vs asthma, allergic rhinitis, eczema, and food allergy outcomes. At this point in time, we see the biggest signal between diet diversity and food allergy. The data were a little bit more conflicting, particularly for eczema, where almost a certain number of papers indicated that increased diet diversity may prevent eczema later on in childhood vs no effect on eczema prevention. We even had a few papers that showed increased diet diversity was associated with increased eczema or atopic dermatitis outcomes.

I looked at my own data then to see, when we look a little bit more mechanistic and at IgE production, what happens, and clearly we showed that increased diet diversity by 6 months was associated with reduced sensitization to food allergens. But there was no effect seen on the aeroallergens. So perhaps there is some sort of specific interaction between diet diversity, its effect on the gut microbiome, and food allergen sensitization and food allergy outcomes specifically.

Original post:
Dr Carina Venter on the Gut Microbiome's Role in Allergic Disease - AJMC.com Managed Markets Network

After reading this article, you should be able to:

Identifying common skin conditions in skin of colour (SOC) is inherently difficult for healthcare professionals owing to the lack of inclusivity and representation in medical textbooks and practical training, which have historically focused on Caucasian/light skin tones[1]. These biases in teaching and training have led to delays in diagnosis and appropriate treatment in people of colour, leading to greater morbidity and mortality in this patient group[2,3]. In the UK, 54% of the population is affected by skin disease annually, with 2333% of the UK population having skin conditions that would benefit from medical care. In children, 34% of diseases are skin-related, with atopic eczema affecting 20% of infants[4].

Delayed diagnosis may result in increased severity of a skin condition, leading to increased itching, dryness, skin thickening and hyperpigmentation owing to the prolonged inflammation[5]. This can result in a need for more aggressive and prolonged treatments once a diagnosis is made[2]. A UK study involving 287 GPs showed that, in primary care, malignant melanomas were significantly underdiagnosed in darker skin compared with lighter skin types[6]. The ability to diagnose and understand the main differences in the presentation of redness, inflammation and scaling present in common skin conditions between different skin tones is imperative for pharmacists to properly serve diverse populations[1].

The Fitzpatrick scale (see table) describes skin according to its reaction to sun exposure, which is dependent on the amount of melanin in the skin, and will be used when discussing skin types throughout this article[7].

Darker skin types are more prone to post-inflammatory hyperpigmentation (PIH), as described in an earlier PJ article Common dermatological conditions in skin of colour[1]. The common presentation of redness, scaling and inflammation that is easily visible on fair skin is less likely to present in the same manner in darker skin tones, making diagnosis difficult[8].

Once the correct diagnosis has been made accounting for the potential for variation in presentation in most cases, the management of dermatological conditions is the same regardless of skin type. For this reason, the management of these conditions will not be discussed in detail, but a summary of best practice is included later in the article[2]. This article aims to aid pharmacists in the identification of several common dermatological conditions that pharmacists may encounter in SOC by outlining their characteristic features and any relevant diagnostic questions.

Community pharmacists play a pivotal role in supporting patients of colour who present with inflammatory skin conditions. Patients should be supported and advised on how to manage their symptoms through best use of emollients, lifestyle changes, managing triggers, proper use of prescribed topical treatments, and recognising signs of infection as this would require referral to their GP or dermatologist.

Atopic dermatitis (i.e. eczema) is a commonly occurring chronic inflammatory skin condition that typically presents in the first year of life[9]. Pruritic (i.e. itching), erythematous (i.e. inflamed and red) plaques with fine overlying scale typically develop on the flexor surfaces, such as the skin on the side of a joint that folds; for example, the crooks of elbows, back of the knees and posterior neck[9]. Establishing the length of time the condition has been present is essential, as well as the frequency of flare ups and triggers. Eczema affects 1 in 5 children and 1 in 12 adults in the UK[10]. Differences between incidence in lighter and darker skin tones is not known in the UK; however, a US study has suggested that eczema is more common in black children[11].

Although the general presentation of eczema is considered similar among different skin tones, the appearance may be difficult to recognise in SOC. Presentations such as erythema, which is easily visible in lighter skin tones, is masked in SOC owing to skin being naturally darker. This can lead to late diagnosis, treatment delays and more advanced disease at the point of diagnosis, with hospital admissions shown to be up to six times higher in patients of colour[9,12,13].

There is increased scaling and lichenification (i.e. thickening) in eczema in SOC, compared with fairer skin, which has been linked to genetic mutations, such as the filaggrin or interleukin mutations, and immune pathway differences, such as differences in thymic stromal lymphopoietin, interferon regulatory factor 2 and Toll-like receptor 2 in Asian and black skin, compared with Caucasian skin[9,14].

Signs and symptoms of eczema in SOC include:

The treatment of eczema is not affected by ethnicity or Fitzpatrick skin type[9,14]. However, as PIH is of greater concern than the skin condition itself in SOC, it is important to minimise this risk by managing inflammation with appropriate steroid use and skin hydration with the appropriate emollient application.

A simple skincare routine with a gentle cleanser that does not leave the skin feeling dry after use should be advised. This keeps the skin well hydrated and prevents further dryness and irritation, as this can lead to increased stretching, eczema flares and worsening PIH[18]. Patients with moderate-to-severe dermatitis that are not responding to topical treatments should be referred to their GP for a secondary care referral, as they may benefit from oral treatments such as oral steroids and systemic immunosuppressants. Signs of infection should also be referred for appropriate antibiotic treatment[10].

Psoriasis is an inflammatory skin condition defined by sharply demarcated erythematous (a clear definition and border between inflamed and normal skin), silvery, scaly plaques that are most often seen on the scalp and external flexures; the nails, hands and trunk can also be affected[19].

Inflammatory plaques are typically pruritic and will often result in either post-inflammatory hyper- or hypo-pigmentation in SOC[8]. There is often a ring of intense erythema surrounding the scaly plaques, as well as erythematous papules surrounding existing plaques this is uniform across skin types. Once plaques have resolved, there is decreased scale and central clearing. If nails are involved, look for pitting[20].

When diagnosing psoriasis in SOC, look for sharply demarcated erythematous, silver-scaled plaques. Erythema is more subtle in darker skin tones and papules can appear more pink, violaceous, grey or even dark brown in colour. PIH is common after erythema has resolved in SOC[21]. A patient history should be taken to understand when symptoms first started; if there is a family history; and where on the body plaques often appear, the nature of their appearance and if they are pruritic[22].

For psoriasis that is not responding to treatment, interferes with daily life (prevents the patient from social or physical activities, employment or education) or is causing distress, such as a negative impact on mental health, the patient should be referred to dermatologists in secondary care via a GP[23].

Acneis an inflammatory skin condition of the pilosebaceous units in the skin. Acne lesions are typically classified as inflammatory and consist of papules and pustules, or non-inflammatory lesions, most often referred to as open and closed comedones[24].

Papules are solid, raised palpable lesions that are less than 1cm in diameter. Pustules are of a similar size but are filled with pus[25].

Comedones are defined as pores that are filled with dead skin debris and sebum[25]. Even though the contents of these pores are the same, closed comedones are often referred to as whiteheads because they are under the skin, while open comedones are often called blackheads because of the oxidation of the debris resulting in a black colour.

Post-inflammatory erythema (PIE) is where small, red and flat spots are left behind after the acne lesion heals[25]. PIE, scarring and PIH are possible symptoms of acne, as well as excess oil production[24,26].

Clinically, there is no difference in the appearance of acne lesions in Caucasian skin compared with SOC; however, histologically, there is more inflammation associated with SOC, even with smaller lesions such as comedones. This results in PIH and scarring more commonly occurring in SOC than in Caucasian skin[27].

Acne is the most commonly diagnosed skin condition in SOC[28]. Common differential diagnoses include perioral dermatitis (POD), folliculitis, rosacea and milia.

The following questions can be considered to aid diagnosis, especially in patients with SOC, as sometimes the redness is not fully visible:

Acne treatment can take around six weeks to begin taking effect[29]. However, once acne has healed, PIH can occur, causing skin to appear darker owing to an abnormal release or overproduction of melanin during the healing process[26]. Keloidal scars are firm, smooth and hard growth resulting from scar formation[25]. These types of scars are more commonly seen in SOC in comparison with Caucasian skin as there is more inflammation present, increasing the likelihood of their development[28].

In patients with SOC, the resulting PIH can be more distressing than the acne itself[26]. The duration of PIH can last much longer than the total duration of acne, with epidermal PIH (occurring on the top layer of the skin) taking around 612 months to heal, and dermal PIH (occurring below the epidermis) potentially lasting for years afterwards[26].

There are considerations required for management of acne in SOC. Treatment must be aggressive enough to minimise the risk of recurrence, without causing irritation that leads to PIH; therefore a good balance is needed[26]. This can be achieved by using strengths of treatment that the patient can tolerate without any side effects.

Effective skincare recommendations alongside the treatment should also be considered, as a simple cleanser, moisturiser and sunscreen without any other active ingredients will help reduce the likelihood of irritation and other side effects. This is true for all skin types but will be especially beneficial to patients with SOC to prevent further PIH.

Ringworm (Tinea corporis) is a fungal infection of the skin that presents with a ring-shaped lesion[30]. It can be passed on after contact with infected people and animals, as well as infected items, such as bedsheets, towels and combs[30]. This lesion may be scaly, dry, inflamed and itchy and can appear anywhere on the body, including the scalp (Tinea capitis) and groin (jock itch)[30].

Differential diagnoses include psoriasis, scabies, seborrheic dermatitis and contact dermatitis. The circular lesion is the most common way to identify ringworm and rule out alternatives; however, there are some questions that can be used to rule out differential diagnoses:

Ringworm can sometimes be hard to distinguish when diagnosing patients with SOC because the characteristic redness may be difficult to observe; however, the location of the lesion on the body and the circular rash with scale are the main diagnosing factors.

PIH resulting from inflammatory skin conditions can have a large disease burden in patients with SOC and can be as concerning as the skin condition itself[8]. For this reason, reducing inflammation should be the focus of treatment, while ensuring the risk of side effects from topical treatment is minimised, as skin peeling and irritation can result in PIH[31].

Chronic inflammatory skin conditions can also cause vast psychological distress, owing to the impact of skin disease and the resulting pigmentation which can be severe and for a prolonged period in SOC on self-esteem and self-image, leading to depression and anxiety. It is important to manage the symptoms of the skin condition and monitor the mental health of the patient[32].

Things to consider when diagnosing dermatological conditions in SOC:

1

2

3

5

6

7

8

9

11

12

13

14

15

16

20

24

26

28

31

32

More:
Recognising common skin conditions in people of colour - The Pharmaceutical Journal

Though Tia Mowry is now a mom of two, her road to parenthood wasn't an easy one and she's not afraid to share that with the world in hopes of inspiring others to do the same and feel less alone.

In a recent interview with TODAY Parents, the 43-year-old actress opened up about experiencing years of "debilitating symptoms" before finally being diagnosed with endometriosis, at which point she was also struggling to conceive. Mowry's 20s were plagued by extreme period pain, migraines, and eczema, yet doctors wouldn't take her "seriously," leaving her to feel "lost and alone," according to the publication. Ultimately, a friend advised her to see a gynecological specialist, who diagnosed Mowry with endometriosis. "She's a Black woman from Harvard. Right away, she knew exactly what it was," shared Mowry. (Related: Why the U.S. Desperately Needs More Black Female Doctors)

Tia-Mowry-Endo-and-Conception-Journey-GettyImages-464350074

Getty Images

ICYDK, endometriosis (aka endo) is a painful, chronic condition wherein tissue that's similar to the lining of the uterus (the endometrium) grows in other places of your body, most commonly on the ovaries, on the fallopian tubes, behind the uterus, or on the bowels or bladder, according to the Office on Women's Health. While endo is one of the most common reproductive health concerns in the U.S., getting diagnosed with the pelvic disorder can take anywhere from four to 11 years, according to an article published in the American Journal of Obstetrics and Gynecology. And the journey to finally feeling heard and getting answers can be even longer for Black women. In fact, research shows that, compared to their white counterparts, Black women are less likely to be diagnosed with the condition overall and that's not because they're less likely to have it.

"When she told me that, I couldn't even pronounce the word," Mowry told TODAY Parents of being diagnosed with endometriosis. "It was something that wasn't talked about, but she told me how she knew [based on] my symptoms. I'm a Black woman, and I was in the age range. I was basically a textbook story." (See more: Why Is It So Hard for Black Women to Get Diagnosed with Endometriosis?)

Story continues

In addition to experiencing telltale signs such as excruciating pain during her period and heavy menstrual bleeding details Mowry shared earlier this year during a March 2021 Instagram Live the actress was also struggling to conceive. Unfortunately, endo and infertility often go hand in hand. Case in point: Between 30 and 50 percent of women with endometriosis may experience infertility, according to the American Society for Reproductive Medicine.

"I never heard the word 'infertility' growing up. It just wasn't part of conversations with my family and friends," she told TODAY Parents. "We as women growing up, we are just like, 'Okay, I'm going to get married, I'm going to have kids.' You have your life planned out and it doesn't always work that way."

In 2011, Mowry welcomed her son, Cree, now 10, with husband Cory Hardrict. During this first pregnancy, however, the Sister, Sister alum experienced, in her words, "excruciating pain" so much so that her doctors feared she might have an ectopic pregnancy, which occurs when a fertilized egg implants and grows outside the main cavity of the uterus, according to the Mayo Clinic. "When you have endometriosis, you're prone to having an ectopic pregnancy because of the scar tissue," explained Mowry. But she didn't let this experience or the infertility struggles she then faced in the years that followed keep her from trying to conceive a second child. And in 2018, Mowry gave birth to her daughter, Cairo, now 3. (Related: Tia Mowry Has an Empowering Message for New Moms Who Feel Pressured to 'Snap Back')

Fast forward to today, and the mom of two is all about "dismantling the traditional norms that we grow up with when it comes to having a family and starting a family," Mowry told TODAY Parents. "And sharing the challenges and triumphs that come with that. The more awareness and stories we share, the more people won't feel alone or discouraged or depressed."

"And the more we talk about our own stories, the more we get rid of the stigma that comes along with IVF, surrogacy, sperm, and egg donation," she continued. "There are amazing ways that families become families."

Mowry is also encouraging those struggling with health challenges to advocate for themselves and not let doctors downplay what they're going through. "You know your body more than anyone," she said. "You are the one living with what you're going through day in and day out. Don't let anyone tell you that something is not wrong with you."

Read the rest here:
Tia Mowry Experienced Years of 'Debilitating Pain' Before Finally Getting Diagnosed with Endometriosis - Yahoo Lifestyle

TORONTO, Nov. 1, 2021 /CNW/ - November is Eczema Awareness Month and the Eczema Society of Canada (ESC) is asking Canadians to "live the itch" of atopic dermatitis (AD), commonly known as eczema, to help raise awareness around this burdensome symptom.

ECZEMA SOCIETY OF CANADA (CNW Group/Eczema Society of Canada)

The itch of AD is frequently rated as the most bothersome symptom of the condition, and intense itch can bother eczema sufferers day and night. According to ESC's recent survey report Itch in Atopic Dermatitis, 44% of adults with severe AD feel itchy all the time. The report highlighted how itch impacts sleep, work, and relationships for both adults and children who live with the condition.

ESC's itch report also revealed:

46% of adults with moderate or severe AD describe their itch as debilitating

87% of adults with severe AD have scars or marks on their skin due to scratching

76% of children with moderate or severe AD are woken from sleep due to their itch

To raise awareness, ESC invited their Eczema Ambassadors a group of dedicated volunteers who live with moderate and severe forms of AD -- to challenge their friends and family to "live the itch" of AD for 24 hours. Participants were asked to set an alarm to sound off once an hour for 24 hours to replicate the interruption of itch. They would experience the frustration and disruption throughout their day and even overnight; the challenge aimed to provide a small glimpse of what it is like to live with the condition.

ESC Eczema Ambassador Allie challenged her family to take the itch challenge. She shared with ESC: "Eczema runs in my family, and the challenge made us all stop and think about how itch impacts our lives. The Live the Itch Challenge is a great way for people to understand the persistence of the itch from eczema and the interruptions itch causes to daily life."

Allie added: "While I wouldn't wish feeling itchy on anyone, I'd like people to understand how frequent and bothersome itch can be. I hope that by participating in this challenge and having these conversations, we can raise awareness around AD and why sufferers deserve better care and understanding."

Story continues

To follow the "Live the itch" challenge, or to participate follow @EczemaSocietyofCanada and use the hashtag #Livetheitch. To learn more about the itch survey visit http://www.eczemahelp.ca/itch.

About Atopic Dermatitis

AD is a chronic, inflammatory skin condition. It is characterized by periods of dry, itchy, inflamed skin that can crack, ooze, and bleed. These periods of worsening symptoms are known as flares. It is estimated that 11% of children and 7% of adults live with AD.

About the Eczema Society of Canada:

The Eczema Society of Canada is a registered Canadian charity dedicated to improving the lives of Canadians living with eczema. Its mandate is to provide education, support, awareness, advocacy, and research. To learn more, visit http://www.eczemahelp.ca.

SOURCE Eczema Society of Canada

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2021/01/c0884.html

See the rest here:
Eczema Society of Canada challenges Canadians to 'live the itch' of eczema - Yahoo Finance

NEW ORLEANS (November 5, 2021) In 2017, the National Institute of Allergy and Infectious Diseases (NIAID) released guidelines to help parents introduce peanut products to their infants to prevent peanut allergy. A new study being presented at this years American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting reveals that although 58% of those surveyed reported their primary care physician (PCP) discussed early peanut introduction, only 40% of the parents said they received a recommendation to introduce peanut by 11 months of age.

Our survey showed that while PCPs are discussing the idea of early peanut introduction with parents of infants, they arent recommending that most parents begin peanut by 11 months of age, said Christopher Warren, PhD, primary author of the study. We now know that the earlier peanut is introduced, as early as when a child begins solid foods, the better the chance that peanut allergy can be prevented.

The survey gathered responses from 3062 households in an approximately 3-week period in 2021. The parents/caregivers who responded had children between the ages of 7 months and 3.5 years. Among the infants, 11% had eczema significant because eczema is one of the indicators parents and caregivers need to be mindful of as a risk factor for food allergies.

In general, parents/caregivers of children with eczema had a greater awareness of the guidelines (18%), and 69% of those parents/caregivers said their childs PCP had discussed peanut introduction.

Of those we surveyed, only 44% of the parents/caregivers reported introducing peanut by 11 months of age, said Ruchi Gupta, MD, ACAAI member and co-author of the study. And only 13% of all those who responded were aware of the NIAID guidelines. Early peanut introduction should be discussed with parents/caregivers of all infants, including those at higher risk of developing peanut allergy.

Parents should know that most infants are either moderate- or low-risk for developing peanut allergies, and most can have peanut-containing foods introduced at home. Whole peanuts should never be given to infants as they are a choking hazard. More information can be foundhereand also in the ACAAI video featuring Dr. Gupta, Introducing peanut-containing foods to prevent peanut allergy.

Abstract Title: Current US Parent/Caregiver Knowledge, Attitudes, and Behaviors Regarding Dietary Introduction of Peanut Protein During Infancy

Presenter: Christopher Warren, PhD

For more information about peanut allergy, or to find an allergist in your area, visitAllergyandAsthmaRelief.org. The ACAAI Virtual Annual Meeting is Nov. 4-8. For more news and research from the ACAAI Scientific Meeting, go to our newsroom - and follow the conversation on Twitter #ACAAI21.

About ACAAI

The ACAAI is a professional medical organization of more than 6,000 allergists-immunologists and allied health professionals, headquartered in Arlington Heights, Ill. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy, and research. ACAAI allergists are board-certified physicians trained to diagnose allergies and asthma, administer immunotherapy, and provide patients with the best treatment outcomes. For more information and to find relief, visit AllergyandAsthmaRelief.org. Join us on Facebook, Pinterest and Twitter.

Annals of Allergy Asthma & Immunology

Survey

People

Current US Parent-Caregiver Knowledge, Attitudes, and Behaviors Regarding Dietary Introduction of Peanut Protein during Infancy

5-Nov-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Excerpt from:
Four years after release of guidelines, parents still not informed about early peanut introduction - EurekAlert

Investors hungry for stocks that can make big moves in a short amount of time know the biotech industry is the best place to look. A new drug approval, or simply clinical trial results that suggest success can push small-cap stocks through the roof.

Recently, Cara Therapeutics (NASDAQ:CARA),Enanta Pharmaceuticals(NASDAQ:ENTA), Ocugen (NASDAQ:OCGN) made big moves in the right direction. Here's a look at the reasons they climbed higher to see if they can put up larger gains down the road.

Image source: Getty Images.

Shares of Cara Therapeutics have been up and down since the company earned approval for its first drug this August. The stock began surging again recently, rising around 33% during the last week of October even though there wasn't any news from the company.

Cara Therapeutics lead drug, Korsuva is an interesting new opioid that earned FDA approval earlier this year to reduce itching associated with hemodialysis treatment. It's too early to predict profits because Cara Therapeutics and its dialysis clinic partners don't intend to launch Korsuva until next year.

The FDA only approved an intravenously injected version of Korsuva and this isn't a viable drug delivery method for relatively healthy eczema patients. Sales to the hemodialysis crowd are expected to be somewhat limited so investors have their sights set on a much larger population of people with atopic dermatitis, or eczema.

Cara Therapeutics stock crashed in April when an oral version of Korsuva failed to significantly reduce itching for eczema patients in a phase 2 trial after 12 weeks of treatment. The company is pressing on because a sub-group analysis suggests oral Korsuva could work for a more narrowly defined population of mild-to-moderate eczema patients who want to control itching.

Image source: Getty Images.

This biotech stock gained more than 50% in October and its long-term shareholders are doing better still. Enanta Pharmaceutics shares have more than doubled since the beginning of 2021.

Enanta Pharmaceuticals discovers and develops antiviral drugs. Its lead revenue stream comes from AbbVie. The big pharma pays royalties on sales of its treatments for hepatitis C virus (HCV). Unfortunately, royalty revenue for HCV drugs isn't nearly enough to make ends meet and Enanta lost $54 million during the first nine months of 2021.

Investors have been driving Enanta Pharmaceuticals stock higher in anticipation of a new oral antiviral treatment the company is developing for COVID-19 patients. On Oct. 19, 2021, the company presented encouraging data for EDP-235, that drove the stock higher.

Sadly, Enanta Pharmaceuticals only has encouraging pre-clinical data for EDP-235. Trials with people aren't expected to begin until early next year. In the meantime, molnupiravir from Ridgeback Biotherapeutics and its big pharma partner Merck will probably become a well-known oral antiviral treatment for COVID-19. The partners already presented successful results from a phase 3 study and Pfizer isn't far behind with an oral antiviral COVID-19 treatment of its own.

Image source: Getty Images.

Shares of this biotech stock surged around 65% higher in October. Over the past year, hope for a COVID-19 vaccine from Ocugen's overseas partner has pushed the stock more than 4,000% higher.

Ocugen is a clinical-stage biotech without any new drug candidates in late-stage human trials. The company's only important asset at the moment is a co-commercialization deal for Covaxin. This is a COVID-19 vaccine developed by Bharat Biotech of India that probably won't ever generate a significant profit for Ocugen.

Another protein-based vaccine from Novavax already generated successful pivotal trial results. A long-delayed emergency use authorization request from Novavax is expected to reach the FDA by the end of the year.

Ocugen began the process for running clinical trials in the U.S. by submitting an investigational new drug (IND) application to the FDA, on Oct. 27, 2021. A planned phase 3 trial in the U.S. can't get started until that IND gets a green light, which could take months.

There's no telling when U.S. regulators here will begin to review an emergency use request from Ocugen. The FDA could simply use data from a successful pivotal trial Bharat Biotech completed in India. This seems highly unlikely because the agency doesn't need to bend over backward to speed up new vaccine development.

Johnson & Johnson, Moderna, and Pfizer have already provided the United States and Canada with more vaccine doses than they can handle. Since these are the only two territories included in Ocugen's agreement with Bharat Biotech, those commercialization rights probably aren't worth the paper they're printed on. It's probably best to watch this company's story play out from a safe distance.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Follow this link:
3 Explosive Biotech Stocks -- Could They Shoot Even Higher? - Motley Fool

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Heres our process.

Eyelid dermatitis is a common condition that causes the skin on or around the eyelid to become dry, itchy, and irritated.

The term may refer to eczema, psoriasis, or seborrheic dermatitis on the eyelids. When the cause is an allergen or irritant, the condition is called eyelid contact dermatitis.

This article discusses how to manage eyelid dermatitis, using treatments and home remedies. It also looks at the symptoms and causes of the condition.

For all kinds of eyelid dermatitis, people should keep the eye area clean and avoid touching it or scratching. This helps to prevent further irritation or infection.

Where possible, it is helpful to identify and avoid contact irritants and allergens that can cause flare-ups. These can include:

To treat eyelid dermatitis caused by atopic dermatitis (eczema) or psoriasis, and for immediate relief from symptoms, a person can:

People should use corticosteroid creams cautiously as they can lose some of their effectiveness if applied for too long. When used close to the eye, there is a risk of glaucoma if used for long periods of time.

These creams can also induce certain short-term side effect, such as acne, hair growth on the treated areas, and thinning of the skin.

Corticosteroid tablets are reserved for the most severe symptoms, as their side effects can be serious. Possible effects include high blood pressure, diabetes, and osteoporosis.

Dermatitis on the eyelids causes inflammation of the thin, sensitive skin around the eyes. The eyelids become irritated, swollen, dry, and reddened. It can affect one or both of the eyes.

If this condition persists, the eyelids can become thickened in a process called lichenification.

When caused by an irritant or allergen, symptoms typically occur within a few hours or days of contact with a trigger substance. Symptoms should subside when the trigger substance is removed.

Common forms of eyelid dermatitis include:

It is unclear what causes conditions such as atopic dermatitis, though there seems to be a genetic component, and it can run in families.

The following actions may help to prevent outbreaks of eyelid dermatitis:

The causes, types, and triggers of eyelid dermatitis vary. It may be necessary to try several of these actions before finding the most effective ones.

The skin around the eyes is thin and delicate, and so the eyes are especially sensitive to irritation.

While it is hard to predict who will develop eyelid dermatitis, certain factors may increase the likelihood of the condition developing. These include:

It is possible to self-diagnose eyelid dermatitis if the cause is obvious. Through trial and error, it is possible to identify and avoid triggers without the need for medical attention.

A doctor can often diagnose the form of dermatitis through a physical exam. They may ask about risk factors, such as hay fever.

When an allergic reaction is suspected as the cause, a doctor may recommend a patch test. Here, a common allergen is placed on the skin to test for an allergic reaction.

If an irritant is the suspected cause, a repeated open application test (ROAT) can be used. This involves exposing the skin to the irritant over several days to test for problematic skin reactions.

It can be more difficult to determine a specific irritant compared with an allergen.

Some complications that may occur with eyelid dermatitis include:

Eyelid dermatitis poses no serious health risks, though it can be uncomfortable and can interfere with daily life.

In most cases, the symptoms are easily managed with treatment and by avoiding triggers. It can, however, become a long-term and recurring condition.

When triggers cannot be identified or avoided, treatment will be used to manage symptoms as best as possible.

The effectiveness of treatments can depend on the extent of exposure to triggers, and the sensitivity of the skin.

Using strategies to prevent symptoms, such as avoiding itching or rubbing the eyes, will help to improve and reduce the severity or onset of symptoms. A doctor or skin specialist can recommend actions that are most suitable for each person.

Go here to see the original:
Eyelid dermatitis: Treatment, symptoms, and causes